版本:
中国

BRIEF-PhaseRx receives orphan drug designation from FDA for PRX-OTC

Nov 28 PhaseRx Inc -

* Phaserx receives orphan drug designation from FDA for PRX-OTC for the treatment of ornithine transcarbamylase deficiency

* PRX-OTC, which is being developed for treatment of ornithine transcarbamylase deficiency has received orphan drug designation by U.S. FDA Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐